OBJECTIVE: To evaluate changes in both the N-terminal (arginine vasopressin; AVP) and C-terminal (copeptin) fragments of the vasopressin prohormone before, during, and after an ultramarathon race and to assess vasopressin and copeptin concentrations in runners with and without hyponatremia. DESIGN: Observational study. SETTING: Three trials (2 sodium balance and 1 hyponatremia treatment) in 2 separate approximately 160-km footraces [Western States Endurance Run (WSER) and Javelina Jundred (JJ100)]. PARTICIPANTS: Six hyponatremic and 20 normonatremic runners; 19 finishers with 7 completing 100 km. MAIN OUTCOME MEASURES: Plasma AVP ([AVP]p), copeptin ([copeptin]p), sodium ([Na]p), and protein (%plasma volume change; %PV) concentrations. RESULTS: In the WSER Sodium Trial, a 3-fold prerace to postrace increase in both [AVP]p (0.7 ± 0.4 to 2.7 ± 1.9 pg/mL; P < 0.05) and [copeptin]p (10.3 ± 12.5 to 28.2 ± 16.3 pmol/L; nonsignificant) occurred, despite a 2 mEq/L decrease in [Na]p (138.7 ± 2.3 to 136.7 ± 1.6 mEq/L; NS). A significant correlation was noted between [AVP]p and [copeptin]p postrace (r = 0.82; P < 0.05). In the WSER Treatment Trial, despite the presence of hyponatremia pretreatment versus posttreatment ([Na]p = 130.3 vs 133.5 mEq/L, respectively), both [AVP]p (3.2 vs 2.1 pg/mL) and [copeptin]p (22.5 vs 24.9 pmol/L) were well above the detectable levels. A significant correlation was noted between [AVP]p and [copeptin]p 60 minutes after treatment (r = 0.94; P < 0.05). In the JJ100 Sodium Trial, significant correlations were found between [copeptin]p change and %PV change (r = -0.34; P < 0.05) and between [AVP]p change and [Na]p change (r = 0.39; P < 0.05) but not vice-versa. CONCLUSIONS: [Copeptin]p seems to be a reliable surrogate of stimulated [AVP]p during exercise. Nonosmotic vasopressin stimulation occurs during ultradistance running. [Copeptin]p may better reflect chronic (%PV) vasopressin secretion under conditions of endurance exercise.
OBJECTIVE: To evaluate changes in both the N-terminal (arginine vasopressin; AVP) and C-terminal (copeptin) fragments of the vasopressin prohormone before, during, and after an ultramarathon race and to assess vasopressin and copeptin concentrations in runners with and without hyponatremia. DESIGN: Observational study. SETTING: Three trials (2 sodium balance and 1 hyponatremia treatment) in 2 separate approximately 160-km footraces [Western States Endurance Run (WSER) and Javelina Jundred (JJ100)]. PARTICIPANTS: Six hyponatremic and 20 normonatremic runners; 19 finishers with 7 completing 100 km. MAIN OUTCOME MEASURES: Plasma AVP ([AVP]p), copeptin ([copeptin]p), sodium ([Na]p), and protein (%plasma volume change; %PV) concentrations. RESULTS: In the WSER Sodium Trial, a 3-fold prerace to postrace increase in both [AVP]p (0.7 ± 0.4 to 2.7 ± 1.9 pg/mL; P < 0.05) and [copeptin]p (10.3 ± 12.5 to 28.2 ± 16.3 pmol/L; nonsignificant) occurred, despite a 2 mEq/L decrease in [Na]p (138.7 ± 2.3 to 136.7 ± 1.6 mEq/L; NS). A significant correlation was noted between [AVP]p and [copeptin]p postrace (r = 0.82; P < 0.05). In the WSER Treatment Trial, despite the presence of hyponatremia pretreatment versus posttreatment ([Na]p = 130.3 vs 133.5 mEq/L, respectively), both [AVP]p (3.2 vs 2.1 pg/mL) and [copeptin]p (22.5 vs 24.9 pmol/L) were well above the detectable levels. A significant correlation was noted between [AVP]p and [copeptin]p 60 minutes after treatment (r = 0.94; P < 0.05). In the JJ100 Sodium Trial, significant correlations were found between [copeptin]p change and %PV change (r = -0.34; P < 0.05) and between [AVP]p change and [Na]p change (r = 0.39; P < 0.05) but not vice-versa. CONCLUSIONS: [Copeptin]p seems to be a reliable surrogate of stimulated [AVP]p during exercise. Nonosmotic vasopressin stimulation occurs during ultradistance running. [Copeptin]p may better reflect chronic (%PV) vasopressin secretion under conditions of endurance exercise.
Authors: Jeremy A Sandgren; Danny W Linggonegoro; Shao Yang Zhang; Sarah A Sapouckey; Kristin E Claflin; Nicole A Pearson; Mariah R Leidinger; Gary L Pierce; Mark K Santillan; Katherine N Gibson-Corley; Curt D Sigmund; Justin L Grobe Journal: Am J Physiol Regul Integr Comp Physiol Date: 2018-01-24 Impact factor: 3.619
Authors: F Sanchis-Gomar; H Pareja-Galeano; C Perez-Quilis; A Santos-Lozano; C Fiuza-Luces; N Garatachea; G Lippi; A Lucia Journal: Cell Stress Chaperones Date: 2014-09-03 Impact factor: 3.667
Authors: Sherry G Mansour; Thomas G Martin; Wassim Obeid; Rachel W Pata; Karen M Myrick; Lidiya Kukova; Yaqi Jia; Petter Bjornstad; Joe M El-Khoury; Chirag R Parikh Journal: Clin J Am Soc Nephrol Date: 2019-08-14 Impact factor: 8.237
Authors: Anna Aulinas; Francisco J Guarda; Elaine W Yu; Melanie S Haines; Elisa Asanza; Lisseth Silva; Nicholas A Tritos; Joseph Verbalis; Karen K Miller; Elizabeth A Lawson Journal: Neuroendocrinology Date: 2020-02-20 Impact factor: 4.914